Liraglutide Interactions: Alcohol, Caffeine, Food and Other Compounds

What "interaction" means in the liraglutide literature

Liraglutide is a prescription glucagon-like peptide-1 (GLP-1) receptor agonist, given by subcutaneous injection, with approved products in diabetes and weight management; a 2025 review in Australian Prescriber described the injectable drugs used for weight management, their place in therapy and their adverse-effect profiles (PMID 41416056). Because it is a prescription medicine, every question about combining it with anything belongs with the prescribing clinician who holds the person's full medication list.

The word "interaction" is used loosely in public discussion. In the published record it covers at least three different things, and they are not interchangeable:

• Pharmacokinetic interaction — one substance changes the absorption, distribution or clearance of another.
• Pharmacodynamic interaction — two substances act on overlapping systems, so effects add, oppose or amplify.
• Co-intervention — a trial deliberately combines treatments and measures the joint outcome, which is a study design, not evidence of a chemical interaction.

Most of what exists for liraglutide falls into the third category. This page is for educational purposes only and is not medical advice; consult a licensed physician or the prescribing clinician for any question about a specific medicine, combination or health condition.

Liraglutide and alcohol: what the evidence actually covers

The alcohol literature on liraglutide is not an interaction literature. The most directly relevant work in this evidence set is a 2025 JAMA Psychiatry analysis examining the repurposing of semaglutide and liraglutide for alcohol use disorder, which assessed whether these GLP-1 receptor agonists were associated with alcohol use disorder outcomes rather than testing how alcohol and liraglutide behave together in the body (PMID 39535805). That distinction matters: the question researchers asked was whether the drug class changes drinking-related outcomes, not whether drinking changes the drug.

No study in this verified set measured blood alcohol curves, ethanol clearance, or liraglutide plasma concentrations in people who had consumed alcohol. Any statement that alcohol "blocks" or "boosts" liraglutide is therefore not supported by the papers cited here.

The mechanistic reasoning researchers use (labelled as reasoning, not evidence)

Why would anyone expect a GLP-1 drug to touch alcohol behaviour at all? The reasoning runs through central reward and appetite circuitry. A 2022 review in Molecular Metabolism set out how GLP-1 physiology — including central appetite signalling and slowed gastric emptying — informs the pharmacotherapy of obesity (PMID 34626851). Preclinical work has mapped specific routes into the brain: a 2022 Cell Metabolism study reported that tanycytes control hypothalamic liraglutide uptake and that this uptake was required for the drug's anti-obesity actions in mice (PMID 35716660), and a 2014 Diabetes study reported that GLP-1 agonism stimulated brown adipose tissue thermogenesis and browning through hypothalamic AMPK in rodents (PMID 24917578). Those are mechanistic findings about how the drug reaches and acts in the brain. They are the reason investigators formed hypotheses about consumption behaviours — they are not themselves alcohol-interaction data.

Liraglutide and caffeine

There is no dedicated liraglutide–caffeine interaction study in this evidence set. That is a plain statement of absence, not a verdict in either direction. No trial here co-administered caffeine with liraglutide, measured caffeine pharmacokinetics under GLP-1 treatment, or tracked heart rate, blood pressure or gastrointestinal symptoms as a function of caffeine intake during liraglutide therapy.

The mechanistic reasoning researchers use (labelled as reasoning, not evidence)

Two mechanistic threads are commonly raised. First, slowed gastric emptying is a described feature of GLP-1 receptor agonist pharmacology in the 2022 physiology review (PMID 34626851), and in principle anything slowing gastric transit could alter how quickly an orally ingested substance reaches the small intestine — a rate question, not necessarily a total-exposure question. Second, both caffeine and GLP-1 signalling have been linked to energy expenditure, and the rodent thermogenesis work showing brown fat activation via hypothalamic AMPK is the study usually invoked (PMID 24917578). Extrapolating from mouse brown-fat biology to a human drinking coffee is reasoning, not a finding, and the papers here do not close that gap.

Food, meals and fasting

Liraglutide is injected subcutaneously, so food does not gate its absorption the way it does for oral tablets — a pharmacological property, not a trial result. What the literature does describe is the drug's effect on eating. The 2022 review characterised GLP-1 physiology as acting on appetite and gastric emptying, and argued that this physiology underpins the pharmacotherapy of obesity (PMID 34626851). The 2025 Australian Prescriber review covered injectable weight-management drugs in clinical practice, including how they are positioned alongside dietary management (PMID 41416056).

Trials in this set embedded diet as part of the protocol rather than testing fasting windows against liraglutide. In the 2021 New England Journal of Medicine trial, participants with obesity first completed a low-calorie diet phase and were then randomised to exercise, liraglutide 3.0 mg daily, both, or placebo for one year, and researchers reported that the combination group achieved greater reductions in body fat than either single treatment (PMID 33951361). No study here compared intermittent fasting with standard meal patterns during liraglutide treatment.

Exercise as a studied co-intervention

Exercise is the best-characterised companion to liraglutide in this evidence set, because it was randomised rather than observed. The one-year trial described above reported that combining supervised exercise with liraglutide 3.0 mg daily produced greater body-fat reduction than either alone (PMID 33951361). A 2023 randomised controlled trial in Cardiovascular Diabetology reported that combining exercise with GLP-1 receptor agonist treatment reduced severity of metabolic syndrome, abdominal obesity and inflammation (PMID 36841762).

A 2024 secondary analysis in JAMA Network Open examined bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment, and researchers reported that bone mineral density outcomes differed across the groups, with combination treatment preserving bone health relative to the drug-alone condition (PMID 38916894). This is an example of a co-intervention study revealing something neither arm showed on its own.

Other compounds and drug combinations

Combination pharmacotherapy for obesity has its own literature. A 2018 review in Metabolic Syndrome and Related Disorders surveyed combination therapies for obesity and the rationale for pairing agents with complementary mechanisms (PMID 29993319), and a 2021 review in Current Obesity Reports assessed where long-term efficacy and safety of anti-obesity treatment stood at that time (PMID 33410104).

For specific drug pairings, the evidence here is preclinical. A 2024 study in Acta Pharmacologica Sinica reported that empagliflozin and liraglutide ameliorated heart failure with preserved ejection fraction in mice via augmentation of the Erbb4 signalling pathway (PMID 38589689). That is a mouse model of a cardiac phenotype, not a human interaction trial, and the authors' framing was mechanistic. Separately, a 2024 study in Advanced Science reported that liraglutide promoted diabetic wound healing through a Myo1c/Dock5 mechanism, illustrating that much of the current mechanistic work on this molecule addresses tissue biology rather than drug–drug behaviour (PMID 39159301).

Evidence map

Tolerability in combination settings: what studies report

Adverse events in this evidence set were reported at the level of whole treatment programmes rather than as substance-by-substance interactions. The 2025 Australian Prescriber review of injectable weight-management drugs described their adverse-effect profiles, including gastrointestinal effects, as part of prescribing considerations (PMID 41416056). The 2021 Current Obesity Reports review examined long-term efficacy and safety of anti-obesity treatment together, rather than treating efficacy in isolation (PMID 33410104). On a specific endpoint, the 2024 secondary analysis reported that bone mineral density outcomes were less favourable with GLP-1 receptor agonist treatment alone than when it was paired with exercise (PMID 38916894).

None of these papers constitutes an assessment of what happens when an individual combines liraglutide with alcohol, caffeine or another medicine. That assessment is clinical, individual, and belongs to a prescribing clinician with access to the person's history.

How to read gaps in this literature

1. Absence of a study is not absence of an effect — and it is not evidence of safety either. Where no trial exists, this page says so.
2. Co-intervention trials answer a different question than interaction studies. The exercise trials reported joint outcomes (PMID 36841762), not drug-level interference.
3. Animal mechanism work does not transfer directly. The tanycyte uptake findings were in mice (PMID 35716660).
4. Association studies cannot establish causation. The alcohol use disorder analysis examined outcomes associated with prescriptions (PMID 39535805).

Related reading

For the broader evidence base on this molecule — mechanism, trial history and regulatory status — see the overview at PeptideU's liraglutide hub.

References

• Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder (JAMA Psychiatry, 2025)
• GLP-1 physiology informs the pharmacotherapy of obesity (Molecular Metabolism, 2022)
• Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined (The New England Journal of Medicine, 2021)
• Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial (Cardiovascular Diabetology, 2023)
• Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial (JAMA Network Open, 2024)
• Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (Current Obesity Reports, 2021)
• Combination Therapies for Obesity (Metabolic Syndrome and Related Disorders, 2018)
• Injectable drugs for weight management (Australian Prescriber, 2025)
• Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions (Cell Metabolism, 2022)
• GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK (Diabetes, 2014)
• Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway (Acta Pharmacologica Sinica, 2024)
• Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5 (Advanced Science, 2024)